

**RNS Reach**

**Diaceutics PLC**

**Diaceutics forms landmark industry Forum to address the economic barriers preventing patient access to life-changing precision medicines**

**Belfast and London, 19 March 2024** - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces the establishment of its Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum, aiming to urgently address the specific economic gaps limiting the advancement of precision medicine and to enable every patient to get the treatment they deserve.

Co-chaired by Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, and Denny Van Liew, Board Member Emeritus at the Precision Medicine Coalition (PMC) and veteran Solution Architect and Life Sciences Senior Advisor at Red Nucleus, the Forum is composed of leading experts in precision medicine across multiple stakeholders, each bringing extensive experience and insights from their careers.

The solutions and recommendations proposed by the Forum will be shared and opened for discussion at a virtual global summit on May 1<sup>st</sup>, providing a unique opportunity for all members of the precision medicine community to contribute to the culminating white paper recommendations and play a role in shaping the future of precision medicine.

**Susanne Munksted, Chief Precision Medicine Officer of Diaceutics**, commented, *"From our long-standing central position within the precision medicine industry, connecting pharma, labs and patients, we have amassed a wealth of data. Our analysis of this data has enabled us to identify 7 practice gaps that are holding back the uptake of precision medicine, and running through all of them is an economic thread. The industry collectively needs to make precision medicine more economically viable, to ensure that every patient gets the treatment they deserve. The Forum brings together key voices in the industry to collaborate on a best way forward, for all."*

Background to the Forum's formation

In 2022, research undertaken by Diaceutics and The Personalized Medicine Coalition (PMC) and published in The Journal of Clinical Oncology Precision Oncology (JCO) highlighted that 64.4% of advanced non-small cell lung cancer patients in the US may not receive the best treatment for their disease and identified 7 Clinical Practice Gaps limiting patient access to precision medicine.

**Daryl Pritchard, Precision Medicine Coalition's Senior Vice President, Science Policy**, commented, *"The technologies, clinical practices, and financial incentives needed to successfully deliver high-quality health care in the era of personalised medicine differ substantially in comparison to what was needed during decades characterised by less sophisticated approaches."*

*"If the economic challenges providers face in adopting personalised medicine are left unaddressed, patients will suffer as high-value personalised medicine technologies will needlessly be left on the shelf."*

**Sarah Hersey, Vice President of Precision Medicine at Bristol-Myers Squibb** and member of the Forum, stated, *"This forum will serve as a healthy discourse to address the root complexities surrounding precision medicine and economic barriers. Together, the precision medicine community can identify possible solutions to close the clinical care gaps and help increase access to effective treatments for patients in need."*

*"Those of us operating in precision medicine have been aware of the stealthy influence which economics have had on patient testing in precision medicine. This has not always been for the better. Revisiting the 2022 Clinical Practice Gaps research with a deeper focus on the economic barriers preventing patients receiving optimized targeted treatments has brought insightful discussion amongst the Forum members. It was rewarding to see*



platform DXRX - The Diagnostics Network ®

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRADBGDXXXBDGSI